The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,006
Nagaoka, K., Shirai, M., Taniguchi, K., Hosoi, A., Sun, C., Kobayashi, Y., Maejima, K., Fujita, M., Nakagawa, H., Nomura, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001358 · Cited by 68
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Uruga, H., & Mino-Kenudson, M. A. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03030-8 · Cited by 69
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J. V., Venkatraman, D., Dall’Olio, F. G., Cravero, P., Vaz, V. R., Ottaviani, D., Majem, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1744 · Cited by 69
Self-citationAmoroso, V., Gallo, F., Alberti, A., Paloschi, D., Bravo, W. F., Esposito, A., Cosentini, D., Grisanti, S., Pedersini, R., Petrelli, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100787 · Cited by 70
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
New Treatment Options in Advanced Squamous Cell Lung Cancer
Paik, P. K., Pillai, R. N., Lathan, C. S., Alarcon, S. V., & Papadimitrakopoulou, V. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237829 · Cited by 66
Kim, Y.-J., Keam, B., Ock, C.-Y., Song, S., Kim, M., Kim, S. H., Kim, K. H., Kim, J.-S., Kim, T. M., Kim, D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.031 · Cited by 66
Nichetti, F., Ligorio, F., Zattarin, E., Signorelli, D., Prelaj, A., Proto, C., Galli, G., Marra, A., Apollonio, G., Porcu, L., et al. (2019) · Cancers · doi:10.3390/cancers12010067 · Cited by 66
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
Low, J. L., Huang, Y., Sooi, K. W. X., Ang, Y. L. E., Chan, Z. Y., Spencer, K. L., Jeyasekharan, A. D. D., Sundar, R., Goh, B. C., Soo, R. A., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33534 · Cited by 66
Recent advances in preclinical models for lung squamous cell carcinoma
Pan, Y., Han, H., Labbe, K. E., Zhang, H., & Wong, K. (2021) · Oncogene · doi:10.1038/s41388-021-01723-7 · Cited by 68
Immune-based therapies in penile cancer
Joshi, V. B., Spiess, P. E., Necchi, A., Pettaway, C. A., & Chahoud, J. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00617-x · Cited by 66
Muto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 68
Wang, L., Luo, Y., Ren, S., Zhang, Z., Xiong, A., Su, C., Zhou, J., Yu, X., Hu, Y., Zhang, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.014 · Cited by 68
Rossi, G., Pezzuto, A., Sini, C., Tuzi, A., Citarella, F., McCusker, M. G., Nigro, O., Tanda, E. T., & Russo, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.005 · Cited by 66
Kim, R., Keam, B., Hahn, S., Ock, C.-Y., Kim, M., Kim, T. M., Kim, D., & Heo, D. S. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.009 · Cited by 65
Liu, W., Ma, F., Sun, B., Liu, Y., Tang, H., Luo, J., Chen, H., & Luo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756872 · Cited by 70
Zhang, L., Zhou, C., Zhang, S., Chen, X., Liu, J., Xu, F., & Liang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939249 · Cited by 68
Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy
Li, Q., Liu, X., Yan, C., Zhao, B., Zhao, Y., Yang, L., Shi, M., Yu, H., Li, X., & Luo, K. (2023) · Small · doi:10.1002/smll.202206211 · Cited by 68
Self-citationZhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Huemer, F., Lang, D., Westphal, T., Gampenrieder, S. P., Hutarew, G., Weiß, L., Hackl, H., Lamprecht, B., Rinnerthaler, G., & Greil, R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071014 · Cited by 68
A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy
Sánchez‐Alonso, S., Setti-Jerez, G., Arroyo, M., Hernández, T., Martos, M. I., Sánchez-Torres, J. M., Colomer, R., Ramiro, A. R., & Alfranca, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001187 · Cited by 66
Zhong, H., Sun, S., Chen, J., Wang, Z., Zhao, Y., Zhang, G., Chen, G., Zhou, M., Zhou, J., Du, Y., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00431-9 · Cited by 64
Kato, K., Doki, Y., Chau, I., Xu, J., Wyrwicz, L. S., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C., Adenis, A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7235 · Cited by 64
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
Porcu, M., Silva, P. D., Solinas, C., Battaglia, A., Schena, M., Scartozzi, M., Bron, D., Suri, J. S., Willard-Gallo, K. E., Sangiolo, D., et al. (2019) · Cancers · doi:10.3390/cancers11030305 · Cited by 64
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Qiu, Z., Chen, Z., Zhang, C., & Zhong, W. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0143-z · Cited by 64
Egea-Benavente, D., Ovejero, J. G., Morales, M. P., & Barber, D. F. (2021) · Cancers · doi:10.3390/cancers13184583 · Cited by 65
Neal, J. W., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A. S., Christoph, D. C., Bearz, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02166 · Cited by 67
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 65
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 63
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 65
Ruíz-Patiño, A., Arrieta, O. G., Cardona, A. F., Martin, C. M., Raez, L. E., Zatarain-Barrón, Z. L., Barrón, F., Ricaurte, L., Bravo-Garzón, M. A., Mas, L. A., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13272 · Cited by 64
Kato, R., Hayashi, H., Chiba, Y., Miyawaki, E., Shimizu, J., Ozaki, T., Fujimoto, D., Toyozawa, R., Nakamura, A., Kozuki, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000350 · Cited by 63
He, X., Du, Y., Wang, Z., Wang, X., Duan, J., Wan, R., Xu, J., Zhang, P., Wang, D., Tian, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000807 · Cited by 64
Horinouchi, H., Nogami, N., Saka, H., Nishio, M., Tokito, T., Takahashi, T., Kasahara, K., Hattori, Y., Ichihara, E., Adachi, N., et al. (2021) · Cancer Science · doi:10.1111/cas.14980 · Cited by 63
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
Pagni, F., Guerini‐Rocco, E., Schultheis, A. M., Grazia, G., Rijavec, E., Ghidini, M., Lopez, G., Venetis, K., Croci, G. A., Malapelle, U., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215452 · Cited by 61
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Bello, M. G. D., Coco, S., et al. (2020) · Cancers · doi:10.3390/cancers12051125 · Cited by 61
Dudnik, E., Moskovitz, M. T., Rottenberg, Y., Lobachov, A., Mandelboim, R., Shochat, T., Urban, D., Wollner, M., Nechushtan, H., Rotem, O., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1865653 · Cited by 62
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
Wong, S. K., Nebhan, C. A., & Johnson, D. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.786046 · Cited by 66
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Cytology for PD-L1 testing: A systematic review
Gosney, J. R., Boothman, A.-M., Ratcliffe, M., & Kerr, K. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.010 · Cited by 62
Kawazoe, A., Yamaguchi, K., Yasui, H., Negoro, Y., Azuma, M., Amagai, K., Hara, H., Baba, H., Tsuda, M., Hosaka, H., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.002 · Cited by 62
Wang, Z., Zhao, J., Ma, Z., Cui, J., Shu, Y., Liu, Z., Cheng, Y., Leaw, S. J., Wu, Y., Ma, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.007 · Cited by 62
Self-citationAdvances in Small-Cell Lung Cancer (SCLC) Translational ResearchPreprint
Drapkin, B. J., & Rudin, C. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a038240 · Cited by 63
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 62
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 62
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients
Li, J. J. N., Karim, K., Sung, M., Le, L. W., Lau, S. C. M., Sacher, A. G., & Leighl, N. B. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.023 · Cited by 64
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Gu, M., Xu, T., & Chang, P. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211006950 · Cited by 68
Morimoto, K., Yamada, T., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.015 · Cited by 59
The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response
Moatti, A., & Cohen, J. L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.725473 · Cited by 65
Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota
Hu, Z. I., Link, V. M., Lima-Junior, D. S., Delaleu, J., Bouladoux, N. J., Han, S., Collins, N., & Belkaid, Y. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200348119 · Cited by 61
Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 68
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
Tsukita, Y., Tozuka, T., Kushiro, K., Hosokawa, S., Sumi, T., Uematsu, M., Honjo, O., Yamaguchi, O., Asao, T., Sugisaka, J., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6277 · Cited by 72
Zhao, S., Cheng, Y., Wang, Q. J., Li, X., Liao, J., Rodon, J. A., Meng, X., Luo, Y., Chen, Z., Wang, W., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03638-2 · Cited by 67
Self-citationImaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 61
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 63
Qin, B., Jiao, X., Liu, J., Liu, K., He, X., Wu, Y. X., Ling, Y., Duan, X.-P., Qin, W., Wang, Z., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102893 · Cited by 60
Jiang, H., Zheng, Y., Qian, J., Mao, C., Xu, X., Li, N., Cheng, X., Wang, H., Teng, L., Zhou, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07251-z · Cited by 60
Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective
Lang, D., Wahl, G., Poier-Fabian, N., Graf, S., Kiesl, D., Lamprecht, B., & Gabriel, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113483 · Cited by 60
Grivas, P. D., Agarwal, N., Pal, S. K., Kalebasty, A. R., Sridhar, S. S., Smith, J., Devgan, G., Sternberg, C. N., & Joaquim Bellmunt, B. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102187 · Cited by 61
Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment
Koirala, M., & DiPaola, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081801 · Cited by 68
Pacheco, J. M., Camidge, D. R., Doebele, R. C., & Schenk, E. L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00195 · Cited by 60
Skov, B. G., Rørvig, S. B., Jensen, T., & Skov, T. (2019) · Modern Pathology · doi:10.1038/s41379-019-0339-0 · Cited by 60
She, L., Hu, H., Liao, M., Xia, X., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Shen, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.017 · Cited by 60
Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 58
Liu, N., Jiang, A., Zheng, X., Fu, X., Zheng, H., Gao, H., Wang, J., Liang, X., Tian, T., Ruan, Z., et al. (2021) · Journal of Cancer · doi:10.7150/jca.55936 · Cited by 59
Disparities in Lung Cancer Treatment
Harrison, S., Judd, J., Chin, S. N., & Ragin, C. C. R. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01193-4 · Cited by 59
Stares, M., Ding, T.-E., Stratton, C., Thomson, F., Baxter, M. A., Cagney, H. P., Cumming, K., Swan, A. M., Ross, F., Barrie, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100445 · Cited by 58
Teramoto, K., Igarashi, T., Kataoka, Y., Ishida, M., Hanaoka, J., Sumimoto, H., & Daigo, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.013 · Cited by 59
Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity
Tam, E. M., Fulton, R. B., Sampson, J. F., Muda, M., Camblin, A. J., Richards, J. M. J., Koshkaryev, A., Tang, J., Kurella, V. B., Jiao, Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0720 · Cited by 64
Ding, H., Xin, W., Tong, Y., Sun, J., Xu, G., Ye, Z., & Rao, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238536 · Cited by 60
Enright, T. L., Witt, J. S., Burr, A. R., Yadav, P., Leal, T. A. B., & Baschnagel, A. M. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.10.014 · Cited by 60
Chen, Y., Wang, Y., Luo, H., Meng, X., Zhu, W., Wang, D., Zeng, H., & Zhang, H. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00173-3 · Cited by 58
Bracci, S., Dolciami, M., Trobiani, C., Izzo, A., Pernazza, A., d’Amati, G., Manganaro, L., & Ricci, P. (2021) · La radiologia medica · doi:10.1007/s11547-021-01399-9 · Cited by 58
The Landscape of Immunotherapy Resistance in NSCLC
Frisone, D., Friedlaender, A., Addeo, A., & Tsantoulis, P. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.817548 · Cited by 60
Immunotherapy approaches for malignant pleural mesothelioma
Fennell, D. A., Dulloo, S., & Harber, J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00649-7 · Cited by 62
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
Bylicki, O., Barazzutti, H., Paleiron, N., Margery, J., Assié, J., & CHOUAID, C. (2019) · BioDrugs · doi:10.1007/s40259-019-00339-4 · Cited by 60
Low, J. L., Walsh, R. J., Ang, Y. L. E., Chan, G. H. J., & Soo, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919870360 · Cited by 59
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 58
Alessi, J. V., Ricciuti, B., Jimenez-Aguilar, E., Hong, F., Wei, Z., Nishino, M., Plodkowski, A. J., Sawan, P., Luo, J., Rizvi, H. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001007 · Cited by 57
Flieswasser, T., Loenhout, J. V., Boullosa, L. F., Eynde, A. V. D., Waele, J. D., Audenaerde, J. V. V., Lardon, F., Smits, E., Pauwels, P., & Jacobs, J. (2020) · Cells · doi:10.3390/cells9061474 · Cited by 50
Mezquita, L., Preeshagul, I. R., Auclin, É., Saravia, D., Hendriks, L. E. L., Rizvi, H. A., Park, W., Nadal, E., Martín-Romano, P., Ruffinelli, J. C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.011 · Cited by 56
Self-citationAssociation of Immune Checkpoint Inhibitors With Neurologic Adverse Events
Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 63
Yang, J. C., Han, B., Jimenez, E. D. L. M., Lee, J.-S., Koralewski, P., Karadurmuş, N., Sugawara, S., Livi, L., Basappa, N. S., Quantin, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.023 · Cited by 57
Self-citationWang, C., Qiao, W., Jiang, Y., Zhu, M., Shao, J., Ren, P., Liu, D., & Li, W. (2019) · Cancer Medicine · doi:10.1002/cam4.2280 · Cited by 59
Wagner, G., Stollenwerk, H. K., Klerings, I., Pecherstorfer, M., Gartlehner, G., & Singer, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774314 · Cited by 60
Vellanki, P. J., Mulkey, F. A., Jaigirdar, A. A., Rodríguez, L., Wang, Y., Xu, Y., Zhao, H., Liu, J., Howe, G. A., Wang, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4338 · Cited by 60
Bañobre, J. R., Manrique, M. C. A., Mosquera, J., Cortegoso, A., Afonso-Afonso, F. J., Álvarez, N. D. D., Núñez, N. F., Azpitarte-Raposeiras, C., Amenedo, M., Santomé, L., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.07 · Cited by 56
Lee, S.-Y., Shim, H. S., Ahn, B., Lim, S. M., Kim, H. R., Cho, B. C., & Hong, M. H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03052-w · Cited by 52
Lemaire, V., Shemesh, C. S., & Rotte, A. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02111-5 · Cited by 56
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Repurposing nitric oxide donating drugs in cancer therapy through immune modulation
Li, C.-Y., Anuraga, G., Chang, C., Weng, T.-Y., Hsu, H., Ta, H. D. K., Su, P., Chiu, P.-H., Yang, S.-J., Chen, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02590-0 · Cited by 56
Hong, L., Aminu, M., Li, S., Lu, X., Petranović, M., Saad, M. B., Chen, P., Qin, K., Varghese, S., Rinsurongkawong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36328-z · Cited by 56
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Chen, Y., Wang, Z., Jin, Y., Zhao, Q., Liu, Z., Zuo, Z., Ju, H., Cui, C., Yao, J., Zhang, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.016 · Cited by 58
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Frontline immunotherapy for NSCLC — the tale of the tail
Chiang, A. C., & Herbst, R. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0317-y · Cited by 57
Togo, M., Yokobori, T., Shimizu, K., Handa, T., Kaira, K., Sano, T., Tsukagoshi, M., Higuchi, T., Yokoo, S., Shirabe, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0820-z · Cited by 55
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
